Annual Long Term Debt
$258.30 M
+$164.80 M+176.26%
31 December 2023
Summary:
Neurocrine Biosciences annual long term debt is currently $258.30 million, with the most recent change of +$164.80 million (+176.26%) on 31 December 2023. During the last 3 years, it has fallen by -$154.00 million (-37.35%). NBIX annual long term debt is now -41.35% below its all-time high of $440.40 million, reached on 31 December 2021.NBIX Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Debt
$251.40 M
-$4.80 M-1.87%
30 September 2024
Summary:
Neurocrine Biosciences quarterly long term debt is currently $251.40 million, with the most recent change of -$4.80 million (-1.87%) on 30 September 2024. Over the past year, it has increased by +$165.50 million (+192.67%). NBIX quarterly long term debt is now -49.69% below its all-time high of $499.70 million, reached on 31 March 2020.NBIX Quarterly Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Long Term Debt Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +176.3% | +192.7% |
| 3 y3 years | -37.4% | -42.5% |
| 5 y5 years | -33.5% | -47.4% |
NBIX Long Term Debt High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -41.4% | +176.3% | -47.6% | +192.7% |
| 5 y | 5 years | -41.4% | +197.9% | -49.7% | +202.9% |
| alltime | all time | -41.4% | >+9999.0% | -49.7% | >+9999.0% |
Neurocrine Biosciences Long Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $251.40 M(-1.9%) |
| June 2024 | - | $256.20 M(+1.3%) |
| Mar 2024 | - | $252.90 M(-2.1%) |
| Dec 2023 | $258.30 M(+176.3%) | $258.30 M(+200.7%) |
| Sept 2023 | - | $85.90 M(-3.6%) |
| June 2023 | - | $89.10 M(-65.7%) |
| Mar 2023 | - | $259.90 M(+178.0%) |
| Dec 2022 | $93.50 M(-78.8%) | $93.50 M(-3.2%) |
| Sept 2022 | - | $96.60 M(-64.0%) |
| June 2022 | - | $268.60 M(-44.1%) |
| Mar 2022 | - | $480.20 M(+9.0%) |
| Dec 2021 | $440.40 M(+6.8%) | $440.40 M(+0.8%) |
| Sept 2021 | - | $437.10 M(+0.4%) |
| June 2021 | - | $435.30 M(+1.4%) |
| Mar 2021 | - | $429.50 M(+4.2%) |
| Dec 2020 | $412.30 M(+375.5%) | $412.30 M(+396.7%) |
| Sept 2020 | - | $83.00 M(-1.5%) |
| June 2020 | - | $84.30 M(-83.1%) |
| Mar 2020 | - | $499.70 M(+476.4%) |
| Dec 2019 | $86.70 M(-77.7%) | $86.70 M(-81.9%) |
| Sept 2019 | - | $478.07 M(+2.9%) |
| June 2019 | - | $464.65 M(+0.9%) |
| Mar 2019 | - | $460.58 M(+18.6%) |
| Dec 2018 | $388.50 M(+5.1%) | $388.50 M(+2.5%) |
| June 2018 | - | $378.88 M(+1.2%) |
| Mar 2018 | - | $374.21 M(+1.2%) |
| Dec 2017 | $369.62 M(+4810.6%) | $369.62 M(+1.2%) |
| Sept 2017 | - | $365.11 M(+1.2%) |
| June 2017 | - | $360.68 M(+7938.4%) |
| Sept 2010 | - | $4.49 M(-11.9%) |
| June 2010 | - | $5.09 M(-17.4%) |
| Mar 2010 | - | $6.16 M(-26.4%) |
| Sept 2009 | - | $8.38 M(+204.7%) |
| June 2009 | - | $2.75 M(-8.8%) |
| Mar 2009 | - | $3.02 M(-59.9%) |
| Dec 2008 | $7.53 M | $7.53 M(-84.1%) |
| Sept 2007 | - | $47.44 M(-1.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2007 | - | $47.93 M(-1.2%) |
| Mar 2007 | - | $48.53 M(-1.3%) |
| Dec 2006 | $49.15 M(-8.3%) | $49.15 M(-1.9%) |
| Sept 2006 | - | $50.13 M(-2.1%) |
| June 2006 | - | $51.20 M(-2.3%) |
| Mar 2006 | - | $52.40 M(-2.2%) |
| Dec 2005 | $53.59 M(-9.9%) | $53.59 M(-2.5%) |
| Sept 2005 | - | $54.94 M(-2.6%) |
| June 2005 | - | $56.40 M(-2.7%) |
| Mar 2005 | - | $57.95 M(-2.5%) |
| Dec 2004 | $59.45 M(+83.1%) | $59.45 M(-7.0%) |
| Sept 2004 | - | $63.95 M(+16.4%) |
| June 2004 | - | $54.93 M(+27.5%) |
| Mar 2004 | - | $43.10 M(+32.7%) |
| Dec 2003 | $32.47 M(+515.4%) | $32.47 M(+70.0%) |
| Sept 2003 | - | $19.11 M(-0.1%) |
| June 2003 | - | $19.12 M(+256.6%) |
| Mar 2003 | - | $5.36 M(+1.6%) |
| Dec 2002 | $5.28 M(+46.6%) | $5.28 M(+18.0%) |
| Sept 2002 | - | $4.47 M(+23.1%) |
| June 2002 | - | $3.63 M(+12.6%) |
| Mar 2002 | - | $3.23 M(-10.3%) |
| Dec 2001 | $3.60 M(+57.7%) | $3.60 M(+76.3%) |
| Sept 2001 | - | $2.04 M(-15.7%) |
| June 2001 | - | $2.42 M(+22.6%) |
| Mar 2001 | - | $1.98 M(-13.4%) |
| Dec 2000 | $2.28 M(+8.7%) | $2.28 M(+19.5%) |
| Sept 2000 | - | $1.91 M(+17.4%) |
| June 2000 | - | $1.63 M(-13.6%) |
| Mar 2000 | - | $1.88 M(-10.3%) |
| Dec 1999 | $2.10 M(-4.5%) | $2.10 M(-4.5%) |
| Sept 1999 | - | $2.20 M(-4.3%) |
| June 1999 | - | $2.30 M(+9.5%) |
| Mar 1999 | - | $2.10 M(-4.5%) |
| Dec 1998 | $2.20 M(+214.3%) | $2.20 M(+214.3%) |
| Dec 1997 | $700.00 K(-12.5%) | $700.00 K(-12.5%) |
| Dec 1996 | $800.00 K | $800.00 K(-42.9%) |
| Mar 1996 | - | $1.40 M |
FAQ
- What is Neurocrine Biosciences annual long term debt?
- What is the all time high annual long term debt for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual long term debt year-on-year change?
- What is Neurocrine Biosciences quarterly long term debt?
- What is the all time high quarterly long term debt for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly long term debt year-on-year change?
What is Neurocrine Biosciences annual long term debt?
The current annual long term debt of NBIX is $258.30 M
What is the all time high annual long term debt for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual long term debt is $440.40 M
What is Neurocrine Biosciences annual long term debt year-on-year change?
Over the past year, NBIX annual long term debt has changed by +$164.80 M (+176.26%)
What is Neurocrine Biosciences quarterly long term debt?
The current quarterly long term debt of NBIX is $251.40 M
What is the all time high quarterly long term debt for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly long term debt is $499.70 M
What is Neurocrine Biosciences quarterly long term debt year-on-year change?
Over the past year, NBIX quarterly long term debt has changed by +$165.50 M (+192.67%)